Instil Bio, Inc. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
Instil Bio, Inc. (TIL) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $44.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-08-13
- Instil Bio, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $22.80M, a 40.47% decline year-over-year.
- Instil Bio, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-03-31 was $22.00M, a 53.59% decline year-over-year.
- Instil Bio, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $25.20M, a 36.04% decline year-over-year.
- Instil Bio, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $25.00M, a 46.81% decline year-over-year.
- Instil Bio, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $135.90M, a 31.40% decline from fiscal 2024.
- Instil Bio, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $198.10M, a 45.23% decline from fiscal 2023.
- Instil Bio, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $361.70M, a 58.20% decline from fiscal 2022.
- Instil Bio, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $865.35M, a 25.23% increase from fiscal 2021.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $44.80M 10-Q · filed 2026-08-13 | $70.00M derived: sum of 3 quarters · filed 2026-08-13 | $95.00M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $22.00M 10-Q · filed 2026-05-15 | $47.20M derived: sum of 2 quarters · filed 2026-05-15 | $72.20M derived: sum of 3 quarters · filed 2026-05-15 | $110.50M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $25.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $50.20M derived: sum of 2 quarters · filed 2026-03-27 | $88.50M derived: sum of 3 quarters · filed 2026-08-13 | $135.90M 10-K · filed 2026-03-27 |
| 2025-09-30 | $25.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $63.30M derived: sum of 2 quarters · filed 2026-08-13 | $110.70M 10-Q · filed 2025-11-13 | $150.10M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $38.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $85.70M 10-Q · filed 2026-08-13 | $125.10M derived: sum of 3 quarters · filed 2026-08-13 | $172.10M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $47.40M 10-Q · filed 2026-05-15 | $86.80M derived: sum of 2 quarters · filed 2026-05-15 | $133.80M derived: sum of 3 quarters · filed 2026-05-15 | $185.60M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $39.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $86.40M derived: sum of 2 quarters · filed 2026-03-27 | $138.20M derived: sum of 3 quarters · filed 2026-03-27 | $198.10M 10-K · filed 2026-03-27 |
| 2024-09-30 | $47.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $98.80M derived: sum of 2 quarters · filed 2025-11-13 | $158.70M 10-Q · filed 2025-11-13 | $222.10M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $51.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $111.70M 10-Q · filed 2025-08-13 | $175.10M derived: sum of 3 quarters · filed 2025-08-13 | $254.60M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $59.90M 10-Q · filed 2025-05-13 | $123.30M derived: sum of 2 quarters · filed 2025-05-13 | $202.80M derived: sum of 3 quarters · filed 2025-05-13 | $316.60M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $63.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $142.90M derived: sum of 2 quarters · filed 2025-03-04 | $256.70M derived: sum of 3 quarters · filed 2025-03-04 | $361.70M 10-K · filed 2025-03-04 |
| 2023-09-30 | $79.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $193.30M derived: sum of 2 quarters · filed 2024-11-13 | $298.30M 10-Q · filed 2024-11-13 | $452.65M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $113.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $218.80M 10-Q · filed 2024-08-13 | $373.15M derived: sum of 3 quarters · filed 2024-08-13 | $508.15M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $105.00M 10-Q · filed 2024-05-10 | $259.35M derived: sum of 2 quarters · filed 2024-05-10 | $394.35M derived: sum of 3 quarters · filed 2024-05-10 | $619.85M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $154.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $289.35M derived: sum of 2 quarters · filed 2024-03-21 | $514.85M derived: sum of 3 quarters · filed 2024-03-21 | $865.35M 10-K · filed 2024-03-21 |
| 2022-09-30 | $135.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $360.50M derived: sum of 2 quarters · filed 2023-11-13 | $711.00M 10-Q · filed 2023-11-13 | $1.20B derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $225.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $576.00M 10-Q · filed 2023-08-14 | $1.06B derived: sum of 3 quarters · filed 2023-08-14 | $1.27B derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $350.50M 10-Q · filed 2023-05-11 | $836.50M derived: sum of 2 quarters · filed 2023-05-11 | $1.04B derived: sum of 3 quarters · filed 2023-05-11 | $1.04B derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $486.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $691.00M derived: sum of 2 quarters · filed 2023-03-31 | $691.00M derived: sum of 3 quarters · filed 2023-03-31 | $691.00M 10-K · filed 2023-03-31 |
| 2021-09-30 | $205.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $205.00M derived: sum of 2 quarters · filed 2022-11-14 | $205.00M 10-Q · filed 2022-11-14 | $205.00M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $0.00 10-Q · filed 2022-08-12 | $0.00 derived: sum of 3 quarters · filed 2022-08-12 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-16 | $0.00 derived: sum of 2 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $0.00 10-K · filed 2022-03-07 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |